Silo Pharma Diversifies into AI with Qwikagents Asset Acquisition, Targeting $47-$53 Billion Market by 2030
Silo Pharma expands beyond biopharmaceuticals into artificial intelligence by acquiring Qwikagents.ai's assets, aiming to capitalize on the rapidly growing AI agent market while advancing its PTSD drug program.
